Published in Blood Weekly, August 16th, 2007
"NPY inhibited the formation of osteoclast-like cells induced by isoprenaline but not that by 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) or soluble receptor activator of nuclear factor-kappa B ligand (RANKL); and it suppressed the production of RANKL and cyclic AMP...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.